GHK-CU 100mg Research Peptide: Advanced Laboratory Guide
⚠️ Research Use Only. GHK-CU 100mg is supplied strictly for in-vitro laboratory research. It is not intended for human consumption, therapeutic, diagnostic, or clinical use. All information below reflects peer-reviewed preclinical and scientific literature only. This content is not medical advice. Ascend Peptides UK accepts no liability for misuse of this product GHK-CU is one of the most scientifically documented copper-binding peptides in biochemical research. First isolated from human plasma in the early 1970s, this naturally occurring glycine-histidine-lysine copper complex has accumulated one of the most extensive published evidence bases of any research tripeptide spanning skin biology, extracellular matrix research, antioxidant signalling, angiogenesis models, and genomic studies involving has been associated with differential expression of thousands of genes in transcriptomic studies. This guide focuses specifically on the GHK-CU 100mg research format the compound’s advanced-quantity option, designed for established research programmes with higher throughput requirements, multi-arm experimental designs, and institutional laboratory settings where extended single-batch consistency matters as much as the science itself. This guide is written for two audiences: laboratory scientists and research professionals who are building or expanding research programmes incorporating this copper peptide complex, and scientifically engaged individuals who want to understand the full scope of what makes this compound one of the most scientifically versatile tripeptides available to UK researchers today. All content here relates strictly to laboratory research and scientific investigation. Ascend Peptides UK supplies GHK-CU 100mg as a high-purity research peptide for laboratory use only not for human consumption, cosmetic application, veterinary, or clinical use of any kind. What Is GHK-CU? Structure, Origin, and Unique Properties GHK-CU is a naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine. The peptide component GHK consists of three amino acids: glycine, histidine, and lysine. The CU designation refers to copper (II), which the tripeptide binds with remarkably high affinity through a coordination involving the imidazole group of histidine and the free amino terminus of the glycine residue. This copper-binding characteristic is not incidental; it is the defining feature of the compound’s biochemical identity and the basis for much of its documented laboratory activity. Copper is an essential trace element involved in a wide range of enzymatic processes in biological systems, including collagen crosslinking, free radical neutralisation, and angiogenic signalling. GHK’s ability to chelate and transport copper ions with precision in laboratory models has made it a subject of research interest across disciplines far beyond its initial discovery context in skin biology. GHK-CU Molecular Identity: Reference Table Identifier Value Full name Copper(II) glycyl-L-histidyl-L-lysine Common name GHK-Cu / Copper peptide Tripeptide sequence Gly-His-Lys (Glycine-Histidine-Lysine) Copper ion Cu(II) — bound via His imidazole + N-terminal amine Molecular formula C14H24CuN6O4 (approximate) Molecular weight ~340.84 Da (GHK tripeptide component: ~340 Da) Natural source Human plasma, saliva, urine CAS number 89030-95-5 Supplied form Lyophilised powder, blue-green tinted to off-white Research quantity 100mg per vial Category Skin Research Peptide / Copper-binding tripeptide What distinguishes this compound from most other research peptides is the extraordinary breadth of its documented influence on cellular behaviour in laboratory models. Published genome-wide studies have reported interactions with over-differential expression of thousands of genes in transcriptomic studies that have no parallel in the research tripeptide category and positions GHK-CU as one of the most far-reaching small peptide tools available to modern biochemical research programmes. Mechanism of Action: How GHK-CU Behaves in Laboratory Models Understanding the mechanisms through which GHK-CU acts in research settings is essential for designing rigorous experiments and interpreting results correctly. The compound operates through several interconnected pathways, many of which have been independently verified across a substantial body of peer-reviewed research. Key Mechanisms Identified in Published Laboratory Research Mechanism How It Works in Research Models Key Enzymes / Pathways Copper chaperone activity Delivers Cu(II) ions to copper-dependent enzymes Lysyl oxidase, Superoxide dismutase (SOD) Collagen/ECM regulation Modulates fibroblast gene expression and ECM protein synthesis Collagen I, III, fibronectin, laminin Antioxidant signalling Upregulates antioxidant enzyme expression in cell models SOD, catalase, glutathione peroxidase Anti-inflammatory signalling Modulates pro-inflammatory cytokine activity TNF-α, IL-6, NF-κB pathway Angiogenic pathway activation Stimulates angiogenic signalling in vascular research models VEGF, FGF pathway components Gene expression modulation Documented interactions with 4,000+ human genes in genome-wide studies Tissue remodelling, stem cell, metabolic gene networks It is important for researchers to note that these mechanisms have been studied predominantly in in vitro cell culture models and animal research systems. None of this research constitutes clinical evidence of efficacy in human subjects, and GHK-CU is supplied strictly for research purposes only. Why GHK-CU 100mg? The Case for the Advanced Research Format The choice between GHK-CU 50mg and GHK-CU 100mg is not simply a question of quantity, it reflects the scale, ambition, and design of your research programme. For researchers moving beyond preliminary investigations into established, multi-arm, or institutionally funded studies, the 100mg format offers meaningful advantages that the smaller quantity cannot match. Consideration GHK-CU 50mg GHK-CU 100mg Best suited for Pilot studies, method development, early-stage research Established programmes, high-throughput assays, multi-arm studies Dose-response studies Limited concentration range Full concentration range (0.1nM–100µM+) Cost per milligram Higher (smaller quantity) Lower — better value for active programmes Multi-assay capacity Single assay type Multiple assay types from single batch Batch consistency Single batch reference Extended single-batch use — fewer batch changes Institutional procurement Individual researchers, smaller labs Core facilities, institutional labs, CROs Reconstitution aliquots Fewer aliquots possible Greater number of single-use aliquots Purity specification ≥98% HPLC-verified ≥98% HPLC-verified (identical standard) The most significant practical advantage of the 100mg format is batch consistency. Every lyophilised peptide compound carries inherent variation between production batches, even when manufactured under tightly controlled conditions. For researchers running extended experimental programmes particularly those publishing results or contributing data to systematic reviews working from a single 100mg batch throughout a study eliminates batch-to-batch variation as a confounding variable. This is a standard requirement in serious laboratory research that is easily overlooked when ordering in smaller increments. Researchers who are earlier in their GHK-CU programme, or who are validating methods before committing to larger-scale work, may find our GHK-CU 50mg
TB-500 10mg vs BPC-157 10mg Research Peptide: Complete Comparison Guide
⚠️ Research Use Only. TB-500 10mg vs BPC-157 10mg is supplied strictly for in-vitro laboratory research. It is not intended for human consumption, therapeutic, diagnostic, or clinical use. All information below reflects peer-reviewed preclinical and scientific literature only. This content is not medical advice. Ascend Peptides UK accepts no liability for misuse of this product When UK researchers are building a laboratory programme around recovery research peptides, two compounds appear more frequently than any other in the scientific literature: the TB-500 10mg research peptide and the BPC-157 10mg research peptide. Both sit within the Recovery Research Peptide category, both are widely studied across cellular biology and tissue-related research models, and both are available from Ascend Peptides UK with same-day dispatch and independently verified Certificates of Analysis from Janoshik. But despite sharing a category label, the TB-500 10mg research peptide and the BPC-157 10mg research peptide are mechanistically distinct compounds. They operate through entirely different molecular pathways, have been studied in different experimental contexts, and are appropriate for different research objectives. Selecting between them or deciding whether both are needed requires a clear understanding of what each compound actually studies at the molecular level in Laboratory models. This guide provides exactly that: a complete scientific comparison of the TB-500 10mg research peptide and the BPC-157 10mg research peptide, written specifically for UK-based researchers and laboratory professionals. For individual compound guides, see our dedicated TB-500 10mg research peptide guide and BPC-157 10mg research peptide guide. All content relates strictly to laboratory research. Both compounds are supplied for scientific research use only — not for human consumption, veterinary, or clinical application. What are the TB-500 10mg and BPC-157 10mg Research Peptides? Understanding what each compound is at the molecular level is the essential starting point for any meaningful comparison. These are not different formulations of the same molecule; they are structurally unrelated peptides derived from entirely different source proteins, with different amino acid chain lengths, molecular weights, and mechanisms. The TB-500 10mg Research Peptide The TB-500 10mg research peptide is a synthetic heptapeptide, seven amino acids in length, with the sequence Ac-LKKTETQ. It corresponds to amino acids 17 through 23 of Thymosin Beta-4, a naturally occurring 43-amino acid protein encoded by the TMSB4X gene. This specific region represents the actin-binding domain of Thymosin Beta-4, which is the structural basis for TB-500’s primary laboratory activity as studied in cell models: binding to globular actin (G-actin) and modulating the balance between monomeric and filamentous actin in cell models. With a molecular weight of 889.02 g/mol and molecular formula C38H68N10O14, the TB-500 10mg research peptide is the smaller of the two compounds and is primarily used in studies examining cytoskeletal dynamics, cell migration, and extracellular matrix interactions. The BPC-157 10mg Research Peptide The BPC-157 10mg research peptide is a synthetic pentadecapeptide, fifteen amino acids in length, derived from a partial sequence of the body protection compound protein found in gastric juice. At a molecular weight of approximately 1,419.53 g/mol (C62H98N16O22), BPC-157 is substantially larger than TB-500. Its primary documented mechanism in laboratory preclinical research involves the nitric oxide (NO) signalling system, specifically modulation of nitric oxide synthase (NOS) activity in vascular and tissue cell models. Beyond the NO pathway, BPC-157 has been documented interacting with vascular endothelial growth factor (VEGF) signalling and epidermal growth factor (EGF) receptor pathways in preclinical models, making it a multi-pathway compound with a broader mechanistic footprint than the more targeted TB-500 10mg research peptide. TB-500 10mg vs BPC-157 10mg Research Peptide: Molecular Comparison Property TB-500 10mg Research Peptide BPC-157 10mg Research Peptide Full scientific name Thymosin Beta-4 Fragment(Ac-LKKTETQ) Body Protection Compound-157(pentadecapeptide) Amino acid length 7 amino acids (heptapeptide) 15 amino acids (pentadecapeptide) Molecular weight 889.02 g/mol 1,419.53 g/mol Molecular formula C38H68N10O14 C62H98N16O22 Peptide origin Thymosin Beta-4 — TMSB4X gene (AA 17–23) Gastric juice body protection compound Primary mechanism Actin-binding (G-actin sequestration) Nitric oxide pathway + VEGF + EGF receptor Research category Recovery Research Peptide Recovery Research Peptide SERP features (Google) Video, People Also Ask, Related searches Sitelinks, Video, Related searches, Discussions KD (keyword difficulty) KD 14 KD 17 WADA status Listed on WADA Prohibited List Listed on WADA Prohibited List Available from Ascend ✓ TB-500 10mg — In Stock ✓ BPC-157 10mg — In Stock The most critical distinction in this table for experimental design is the primary mechanism row. The TB-500 10mg research peptide operates through actin-binding and cytoskeletal modulation, a pathway entirely separate from the nitric oxide and growth factor signalling activity of the BPC-157 10mg research peptide. These two compounds are not interchangeable. Results from studies using one cannot be used to predict the behaviour of the other in the same experimental system, and protocols designed for one will not produce valid data if the other is substituted. Mechanisms of Action: How Each Research Peptide Works How the TB-500 10mg Research Peptide Works The TB-500 10mg research peptide acts primarily by binding to globular actin (G-actin), the monomeric form of actin, and sequestering it from polymerisation into filamentous actin (F-actin). This disruption of the actin monomer-polymer equilibrium has measurable downstream effects on cytoskeletal organisation, cell shape, mechanical stiffness, and directed motility in laboratory cell models. Published research using scratch assays and transwell migration models has examined how this actin modulation influences directed cell movement and chemotaxis. Separately, the foundational research by Malinda et al. using rodent models established a relationship between Thymosin Beta-4 administration and collagen fibre organisation, which underpins much of the interest in the TB-500 fragment for tissue biology research. TB-500 has also been studied in the context of inflammatory signalling, with experimental models examining its relationship to NF-κB pathway activity and pro-inflammatory cytokine release in in vitro systems. How the BPC-157 10mg Research Peptide Works The BPC-157 10mg research peptide operates through a mechanistically distinct axis. Its primary documented activity involves the nitric oxide (NO) signalling pathway, specifically its influence on nitric oxide synthase (NOS) activity in vascular and tissue cell models. Nitric oxide is a critical signalling molecule involved in vasodilation, angiogenic responses,
Buy Tesamorelin 5mg Research Peptide UK: Complete Science Guide
⚠️ Research Use Only. Tesamorelin 5mg is supplied strictly for in-vitro laboratory research. It is not intended for human consumption, therapeutic, diagnostic, or clinical use. All information below reflects peer-reviewed preclinical and scientific literature only. This content is not medical advice. Ascend Peptides UK accepts no liability for misuse of this product If you are looking to buy Tesamorelin 5mg research peptide in the UK only for a laboratory programme, this guide covers everything you need to make an informed sourcing and experimental design decision. Tesamorelin 5mg is the entry-format version of one of the most scientifically distinctive GHRH research compounds available, a full-length GHRH analogue with N-terminal stabilisation that gives it a unique receptor engagement profile no other GHRH research peptide can replicate. This guide is written for two audiences: UK-based laboratory researchers and research professionals evaluating tesamorelin 5mg for their first research programme or a pilot investigation, and scientifically engaged individuals who want to understand what this compound is, how it works, and why the 5mg format is the appropriate entry point for initial research work with this GHRH analogue. All content below relates strictly to laboratory research and scientific investigation. Ascend Peptides UK supplies tesamorelin 5mg as a high-purity research peptide for laboratory use only, not for human consumption, veterinary, or clinical application of any kind. What Is Tesamorelin? Structure and Scientific Identity Tesamorelin is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH), the endogenous hypothalamic peptide responsible for stimulating GH secretion from anterior pituitary somatotroph cells. What makes Tesamorelin 5mg research peptide scientifically distinct from every other GHRH research compound available in the UK is a combination of two structural features that no other GHRH analogue shares simultaneously. First, tesamorelin replicates the full 44-amino acid sequence of native GHRH, not a truncated version. Most other GHRH research peptides, including CJC-1295 without DAC and Sermorelin, are based on only the first 29 amino acids of the endogenous peptide. The full-length sequence means tesamorelin engages the entire GHRH receptor binding interface, providing a receptor interaction profile that more closely reflects the endogenous ligand. Second, tesamorelin carries a trans-3-hexenoic acid group covalently bonded to the N-terminal tyrosine residue. This modification is the source of its substantially improved resistance to DPP-IV (dipeptidyl aminopeptidase IV) enzymatic degradation, the primary enzyme responsible for the rapid breakdown of native GHRH in biological environments. The result is a GHRH research compound that is designed to resist enzymatic degradation longer than native GHRH in laboratory conditions in research conditions than unmodified GHRH. Tesamorelin 5mg Molecular Identity — Quick Reference Identifier Value Scientific name Tesamorelin (INN) Type full-length 44-amino-acid GHRH analogue N-terminal modification Trans-3-hexenoic acid group on N-terminal tyrosine Molecular formula C221H366N72O67S Molecular weight ~5,135.94 Da Receptor target GHRH receptor (GHRHR) — Gs-coupled GPCR Research category Growth Hormone Research Peptide Supplied form Lyophilised powder — white to off-white Format 5mg per vial (also available: 10mg) Third-party testing Janoshik — HPLC + LC-MS verified Why Buy Tesamorelin 5mg Research Peptide? The Case for the Entry Format Researchers looking to buy tesamorelin 5mg research peptide are typically at one of two stages in their programme: either beginning their first investigation with this GHRH analogue and wanting to validate methods before committing to larger quantities, or running smaller-scale studies where the compound volume requirements do not justify the 10mg format. Both are entirely valid scientific rationales for the 5mg format. Consideration Tesamorelin 5mg Tesamorelin 10mg Best suited for Pilot studies, method development, preliminary investigations Established programmes, multi-arm studies, high-throughput assays Research stage Early-stage or first-time tesamorelin research Confirmed demand, ongoing programme Dose-response capability Limited concentration range Full concentration gradient studies Cost per milligram Higher per mg — smaller quantity Better value — larger quantity Batch consistency Single batch for pilot Extended single-batch use Aliquots possible Fewer single-use aliquots A greater number of aliquots Ideal researcher type First-time buyers, pilot-study users, small labs Active programmes, institutions, CROs Purity standard ≥98% HPLC-verified ≥98% HPLC-verified (identical standard) The most important practical advantage of starting with the tesamorelin 5mg research compound is risk management. When working with a GHRH analogue for the first time, establishing reconstitution protocols, validating assay conditions, and confirming that the compound behaves as expected in your specific cell model or experimental system, committing to the 10mg format before method validation is complete is unnecessary. The 5mg format provides sufficient material to run pilot assays and generate preliminary data, after which the 10mg format becomes the appropriate choice for the full programme. For researchers who have already validated their tesamorelin protocols and are ready for a larger programme, our dedicated tesamorelin 10mg research peptide guide covers the advanced format in full, including why single-batch consistency matters for established programmes and how the 10mg format supports high-throughput assay designs. How Tesamorelin 5mg Works in Laboratory Research Models Understanding the mechanism of the tesamorelin 5mg research peptide is essential for designing rigorous experimental protocols and interpreting results correctly. Tesamorelin acts as a selective agonist (preclinical and clinical research models) at the GHRH receptor (GHRHR), a Gs-coupled G-protein-coupled receptor expressed predominantly on anterior pituitary somatotroph cells. GHRHR Signalling Cascade When tesamorelin binds to GHRHR, it initiates the following signalling sequence in laboratory research models: GHRHR activation → Gs protein stimulation → adenylyl cyclase activation → intracellular cAMP elevation Elevated cAMP → protein kinase A (PKA) activation → downstream transcription factor phosphorylation PKA activation → increased GH mRNA transcription → pulsatile growth hormone secretion from somatotroph cells GH secretion → hepatic IGF-1 production → downstream growth factor signalling cascade Because the tesamorelin 5mg research compound uses the full 44-amino acid GHRH sequence, it engages the complete GHRHR binding interface, a mechanistically important distinction from shorter GHRH analogues. For researchers studying receptor structure-function relationships or designing experiments that require maximal and physiologically relevant GHRH receptor engagement, this full-length engagement profile is a significant experimental advantage. Research Applications of Tesamorelin 5mg in Laboratory Settings The tesamorelin 5mg research peptide is used across a range of scientific disciplines within the Growth Hormone Research Peptide category.
Ipamorelin 5mg Research Peptide UK: Science and Lab Applications Guide
⚠️ Research Use Only. Ipamorelin 5mg is supplied strictly for in-vitro laboratory research. It is not intended for human consumption, therapeutic, diagnostic, or clinical use. All information below reflects peer-reviewed preclinical and scientific literature only. This content is not medical advice. Ascend Peptides UK accepts no liability for misuse of this product If you work in growth hormone research or study the ghrelin signalling pathway, the ipamorelin 5mg research peptide is likely already on your radar. Among the growth hormone-releasing peptides (GHRPs) available for laboratory research in the UK, ipamorelin occupies a scientifically distinctive position. It is the most receptor-selective GHRP studied in the published literature, offering isolated GH pathway stimulation in research models, with reported to have minimal effects on cortisol or prolactin in research models, two variables that complicate data interpretation when using less selective compounds. This guide covers everything UK-based researchers and laboratory professionals need to understand about the ipamorelin 5mg research peptide, its molecular identity and receptor pharmacology, how it differs from other GHRPs and from GHRH analogues like CJC-1295, its primary laboratory applications, and how to source it to the correct research-grade standard from a UK-based ipamorelin 5mg supplier. All content relates strictly to laboratory research, and any clinical or research data referenced is based on preclinical studies. Ascend Peptides UK supplies ipamorelin 5mg lab research peptide alongside our complete range of high-purity growth hormone research peptides for scientific investigation only, not for human consumption, veterinary, or clinical use. What is the Ipamorelin 5mg Research Peptide? Molecular Identity and Classification Ipamorelin is a synthetic pentapeptide, five amino acids in length, classified as a Growth Hormone Releasing Peptide (GHRP). It is a member of the growth hormone secretagogue (GHS) family of compounds: synthetic molecules that stimulate GH secretion by acting on the ghrelin receptor (GHS-R1a), an entirely different receptor system from the GHRH receptor (GHRHR) targeted by peptides like CJC-1295, without DAC and tesamorelin. The defining characteristic of the ipamorelin 5mg research peptide and the feature that most distinguishes it from other GHRPs in the literature is its exceptional receptor selectivity. In published research models, ipamorelin demonstrates highly selective GH stimulation with minimal effects on cortisol, prolactin, and ghrelin-mediated appetite signalling pathways. This selectivity profile makes it the preferred GHRP for research designs that require isolated GH pathway investigation without the confounding effects that less selective GHRPs introduce. Ipamorelin 5mg — Molecular Identity Quick Reference Identifier Value INN / Common name Ipamorelin Type Synthetic pentapeptide (5 amino acids) — GHRP Peptide sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 Molecular formula C38H49N9O5 Molecular weight 711.85 g/mol Primary receptor GHS-R1a (growth hormone secretagogue receptor 1a) Selectivity profile Highly selective in research models, with limited cortisol/prolactin effects reported Research category Growth Hormone Research Peptide (GHRP) Supplied form Lyophilised powder — white to off-white Format 5mg per vial (also available: 10mg) Third-party testing Janoshik — HPLC + LC-MS verified Understanding the Ghrelin System — The Scientific Foundation To understand why the ipamorelin 5mg research peptide is scientifically significant, it is necessary to first understand the receptor system it targets: the growth hormone secretagogue receptor 1a, or GHS-R1a, commonly known as the ghrelin receptor. Ghrelin is a naturally occurring peptide hormone produced primarily in the stomach, with the hypothalamus and pituitary gland also expressing ghrelin and its receptor. It plays a complex role in biological systems, influencing GH secretion, appetite regulation, energy homeostasis, and metabolic signalling. When ghrelin binds to GHS-R1a, one important effect in research models is stimulation of GH secretion from anterior pituitary somatotroph cells, a pathway entirely separate from, but complementary to, the GHRH-GHRHR pathway. This is a critical distinction for experimental design: the ghrelin pathway and the GHRH pathway represent two independent mechanisms by which GH secretion can be stimulated. Ipamorelin 5mg research peptide specifically targets the ghrelin pathway via GHS-R1a, while GHRH analogues like CJC-1295 without DAC target the GHRH pathway. In research models where both pathways are activated simultaneously, GH secretion is synergistically amplified, the mechanistic basis for why these two peptides are frequently studied together in combined-pathway research protocols. Mechanism of Action: How Ipamorelin 5mg Works in Laboratory Research The ipamorelin 5mg research peptide is studied as a selective agonist at GHS-R1a — the ghrelin receptor expressed on pituitary somatotroph cells, hypothalamic neurons, and other tissue types in relevant research models. When ipamorelin lab research peptide binds to GHS-R1a, it initiates the following signalling cascade in laboratory experimental systems: GHS-R1a activation → Gq protein stimulation → phospholipase C (PLC) activation → IP3 and DAG second messenger production IP3-mediated calcium release from intracellular stores → elevated intracellular Ca²⁺ → somatotroph cell activation DAG-mediated protein kinase C (PKC) activation → downstream GH gene expression and secretion Result: pulsatile GH secretion from anterior pituitary somatotroph cells The selectivity of the ipamorelin 5mg laboratory grade compound for GHS-R1a over other hormone pathways is a defining research advantage. In contrast to GHRP-6 and GHRP-2, two other GHRPs that activate GHS-R1a, ipamorelin demonstrates minimal activation of adrenocorticotropic hormone (ACTH) and cortisol release pathways, and is reported to have limited activation of ACTH, cortisol, and prolactin pathways in published research models. This selectivity means that experimental results reflect GH pathway activity specifically, rather than a combined hormonal response that complicates data interpretation. Ipamorelin 5mg vs Other GHRPs: Why Selectivity Matters in Research Researchers evaluating the ipamorelin 5mg research peptide alongside other GHRPs need to understand why selectivity is the central criterion for choosing between these compounds in laboratory settings. Property Ipamorelin 5mg GHRP-6 GHRP-2 Amino acids 5 (pentapeptide) 6 (hexapeptide) 6 (hexapeptide) Molecular weight 711.85 g/mol 873.04 g/mol 817.94 g/mol Receptor GHS-R1a (selective) GHS-R1a GHS-R1a GH stimulation ✓✓ Strong ✓✓ Strong ✓✓ Strong Cortisol effect ✓ Minimal in research models ✓✓ Notable increase ✓✓ Notable increase Prolactin effect ✓ Minimal in research models ✓✓ Notable increase ✓ Moderate increase Appetite pathway ✗ Minimal ghrelin effect ✓✓ Strong appetite stimulation ✓ Some effect Research selectivity ✓✓ Highest selectivity ✓ Moderate ✓ Moderate Best for Isolated GH pathway research Broad GH + appetite studies GH + cortisol
AOD-9604 10mg Research Peptide UK: Complete Advanced Laboratory Guide
⚠️ Research Use Only. AOD-9604 10mg is supplied strictly for in-vitro laboratory research purposes only. It is not intended for human consumption, therapeutic, diagnostic, or clinical use. All content below reflects peer-reviewed preclinical and published scientific literature only. This content is not medical advice. If your laboratory research programme has moved beyond preliminary investigation into AOD-9604 and requires a compound volume that supports full dose-response protocols, multi-arm experimental designs, and extended batch consistency, the AOD-9604 10mg research peptide is the appropriate format for your next phase of work. The AOD-9604 10mg research peptide is the advanced-format version of the most studied selective lipolysis compound in the UK metabolic research peptide category. Its defining scientific characteristic, selective stimulation of lipolysis through the beta-3 adrenergic receptor pathway without IGF-1 elevation or growth hormone receptor binding, is identical between both formats. What changes at 10mg is research capacity: the ability to run full concentration gradients, parallel experimental arms, and extended single-batch studies without the batch-change variability that limits multi-vial 5mg programmes. This guide is written specifically for UK-based researchers who are already familiar with AOD-9604 at the 5mg level and are evaluating the 10mg format for an established programme. For a complete introduction to AOD-9604 science, mechanism, and first-time research considerations, see our dedicated AOD-9604 5mg research peptide guide. All content relates strictly to laboratory research. The AOD-9604 10mg research peptide is supplied by Ascend Peptides UK for in-vitro research use only, not for human consumption, veterinary, or clinical application. What is the AOD-9604 10mg Research Peptide? AOD-9604 is a synthetic hexadecapeptide derived from the C-terminal region of human growth hormone (hGH) — specifically, amino acids 176 through 191. The “AOD” designation stands for Anti-Obesity Drug, reflecting the original research objective when the compound was developed by scientists at Metabolic Pharmaceuticals in the 1990s. The compound includes a tyrosine (Tyr) residue added to the N-terminus of the native HGH fragment 176-191, a structural modification that distinguishes AOD-9604 from unmodified HGH Fragment 176-191 and contributes to its stability profile in laboratory conditions. The AOD-9604 10mg research peptide retains the defining pharmacological property of the parent fragment: selective stimulation of lipolysis, the breakdown of stored triglycerides in adipocyte cell models through a pathway independent of the growth hormone receptor (GHR) and independent of IGF-1 production. This IGF-1 independence is the single most important experimental advantage of the AOD 9604 10mg research compound for researchers designing metabolic studies: the absence of IGF-1 elevation means that downstream anabolic, mitogenic, or glucose-modulating confounds associated with full-length hGH are not present in AOD-9604 experimental models. AOD-9604 10mg Research Peptide — Molecular Identity Identifier Value Scientific name AOD-9604 (Anti-Obesity Drug 9604) Alternative names HGH Fragment 176-191 / Tyr-hGH Fragment 177-191 / GH Fragment Type Synthetic hexadecapeptide (16 amino acids) N-terminal modification Tyrosine (Tyr) residue added at the N-terminus Molecular formula C78H123N23O23S2 Molecular weight ~1,817.0 Da Origin C-terminal fragment (AA 176-191) of human growth hormone (hGH) Primary mechanism Selective lipolysis via the beta-3 adrenergic receptor pathway IGF-1 independence Does NOT stimulate IGF-1 production — key research advantage GHR binding Does NOT bind growth hormone receptor (GHR) Research category Metabolic Research Peptide Format (10mg) Lyophilised powder — white to off-white Testing standard Janoshik — HPLC + LC-MS verified, ≥98% purity Why Choose AOD-9604 10mg for Research? The Case for the Advanced Format The decision between AOD-9604 5mg and AOD-9604 10mg is not about which compound is superior; the molecular structure, mechanism of action, and purity standard are identical. The decision is about which format is appropriate for the scale and design of your research programme. The aod 9604 10mg research format becomes the correct choice when your experimental design requires one or more of the following: a full dose-response concentration gradient across multiple wells or treatment groups; parallel experimental arms comparing AOD-9604 with other metabolic research compounds; longitudinal studies requiring consistent compound conditions across multiple time points from a single batch; or high-throughput assay designs where vial-to-vial batch variation would introduce unacceptable experimental noise. Research Consideration AOD-9604 5mg AOD-9604 10mg Best suited for Pilot studies, method validation, preliminary investigations Established programmes, multi-arm studies, full dose-response Research stage First-time AOD-9604 research, assay development Confirmed research design, ongoing programme Dose-response range Limited concentration gradient Full dose-response curve capability Number of aliquots Fewer single-use aliquots per vial Greater aliquot volume — fewer batch changes Batch consistency Single-batch for focused pilot series Extended single-batch use — critical for reproducibility Multi-arm protocols Single-compound arms only Supports parallel compound arms simultaneously Cost efficiency Higher per mg — appropriate for pilot stage Better value for active research programmes Institutional suitability CRO pilots, academic method development Institutions, established CROs, multi-researcher labs Purity standard ≥98% HPLC-verified (Janoshik) ≥98% HPLC-verified (Janoshik — identical standard) For researchers beginning their first investigation with this compound and validating assay conditions before committing to a full programme, the AOD-9604 5mg research peptide guide covers the pilot-stage format in detail, including first-time reconstitution protocols and preliminary dose selection considerations. Mechanism of Action: How AOD-9604 10mg Works in Laboratory Research Models Understanding the mechanism of the AOD-9604 10mg research peptide at a molecular level is essential for designing valid experimental protocols and correctly attributing observed outcomes to the compound’s specific activity. Three mechanistic properties define how AOD-9604 behaves in research models. 1. Beta-3 Adrenergic Receptor (β3-AR) Pathway Activation The primary documented mechanism of AOD-9604 in laboratory research models is activation of the beta-3 adrenergic receptor (β3-AR), a G-protein-coupled receptor expressed predominantly in adipose tissue. β3-AR activation triggers a cAMP-mediated signalling cascade that activates hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL), the two primary enzymes responsible for triglyceride hydrolysis in adipocytes. The result is liberation of free fatty acids and glycerol, the defining outcome measured in lipolysis assays using the AOD 9604 10mg research compound. 2. IGF-1 Independence — The Key Research Advantage Unlike full-length hGH, the AOD-9604 10mg research peptide does not bind the growth hormone receptor (GHR) and does not stimulate IGF-1 production through the liver. This independence from the GH-IGF-1 axis is the most
Sermorelin 2mg Research Peptide UK: Complete GHRH Science Guide
⚠️ Research Use Only. Sermorelin 2mg is supplied strictly for in-vitro laboratory research purposes only. It is not intended for human consumption, therapeutic, diagnostic, or clinical use. All content below reflects peer-reviewed preclinical and published scientific literature only. This content is not medical advice. Among the GHRH research peptides available to UK laboratories, the sermorelin 2mg research peptide occupies a scientifically distinct position not because it is the most potent or the longest-acting, but because it is the most physiologically representative. As a synthetic analogue of the first 29 amino acids of native Growth Hormone Releasing Hormone, sermorelin produces pulsatile GH stimulation with the shortest in vitro half-life of any GHRH research analogue, approximately 12 minutes, making it the most accurate molecular tool available for studying the natural kinetics of GHRH receptor activation without the extended DPP-IV protection of modified analogues like CJC-1295 or tesamorelin. The sermorelin 2mg research peptide is the entry-format version of this GHRH analogue appropriate for pilot investigations, pharmacokinetic time-course studies, method development, and first-time GHRH receptor research before scaling to the 5mg format for established programmes. This guide covers its molecular identity, the scientific basis of its unique research value, how it compares to other GHRH analogues, and how to source it from a UK-based sermorelin peptide supplier with same-day dispatch. All content relates strictly to laboratory research. Ascend Peptides UK supplies sermorelin 2mg laboratory grade as part of our complete range of growth hormone research peptides for UK laboratories for in-vitro research use only, not for human consumption, veterinary, or clinical application. What is the Sermorelin 2mg Research Peptide? Molecular Identity Sermorelin, known scientifically as GRF 1-29 NH2, or GHRH(1-29)NH2, is a synthetic peptide corresponding to the first 29 amino acids of the naturally occurring 44-amino acid Growth Hormone Releasing Hormone. Unlike tesamorelin, which replicates the full 44-amino acid GHRH sequence with N-terminal stabilisation, or CJC-1295 without DAC, which introduces four amino acid substitutions for enhanced DPP-IV resistance, sermorelin makes no structural modifications to the first 29 amino acids of native GHRH. It is, in that sense, the most structurally conservative GHRH research analogue, the one most closely resembling the natural ligand. This structural conservatism is both sermorelin’s defining research advantage and its primary pharmacokinetic limitation. Because it carries no DPP-IV protection beyond that provided by the native GHRH sequence itself, the sermorelin 2mg research peptide is degraded relatively rapidly by dipeptidyl aminopeptidase IV in research conditions, producing an in vitro half-life of approximately 12 minutes. This is the shortest half-life of all three major GHRH research analogues, and, for appropriately designed studies, this kinetic property is precisely what makes sermorelin the correct compound to choose. Sermorelin 2mg Research Peptide — Molecular Identity Quick Reference Identifier Value Scientific name Sermorelin (INN) Alternative names GRF 1-29 NH2 / GHRH(1-29)NH2 / Sermorelin Acetate Type Synthetic truncated GHRH analogue — 29 amino acids Molecular formula C149H246N44O42S Molecular weight 3,357.93 Da Receptor target GHRHR (Growth Hormone Releasing Hormone Receptor) — Gs-coupled GPCR Amino acid coverage First 29 AA of native GHRH (44 AA full length) DPP-IV resistance Moderate — less resistant than tesamorelin or CJC-1295 In vitro half-life ~12 minutes — shortest of all GHRH research analogues GH pulse pattern Pulsatile — mirrors natural GH secretion closely Research category Growth Hormone Research Peptide (GHRH Analogue) Format (2mg) Lyophilised powder — white to off-white Testing standard Janoshik — HPLC + LC-MS verified, ≥98% purity How the Sermorelin 2mg Research Peptide Works — GHRHR Signalling The sermorelin 2mg research peptide acts as a selective agonist at the Growth Hormone Releasing Hormone Receptor (GHRHR), a Gs-coupled G-protein-coupled receptor expressed on anterior pituitary somatotroph cells. Upon binding to GHRHR, sermorelin initiates the following signalling cascade in laboratory research models: GHRHR activation → Gs protein stimulation → adenylyl cyclase activation → intracellular cAMP elevation Elevated cAMP → protein kinase A (PKA) activation → phosphorylation of downstream transcription factors PKA activation → increased GH mRNA transcription → pulsatile growth hormone secretion from somatotroph cells GH secretion → hepatic IGF-1 production → downstream growth factor signalling cascade The key mechanistic distinction for experimental design is the relationship between sermorelin’s short half-life and the GH pulse pattern it produces in research models. Because sermorelin is cleared rapidly from the experimental system, approximately 12 minutes, it produces discrete, well-defined GH secretion pulses that closely mirror the natural pulsatile pattern of endogenous GHRH activity. This physiological accuracy makes the ghrh research peptide sermorelin the preferred compound for time-course studies examining GH pulse amplitude, frequency, and decay kinetics, areas where longer-acting analogues like CJC-1295 without DAC produce sustained stimulation that masks these natural dynamics. Why Choose the 2mg Format? Sermorelin 2mg vs 5mg for Research The choice between sermorelin 2mg and sermorelin 5mg is a research-stage decision, not a quality decision. The molecular structure, GHRHR binding affinity, mechanism of action, and purity standard are identical across both formats. What differs is the research capacity each format provides. Research Consideration Sermorelin 2mg Sermorelin 5mg Best suited for Pilot studies, short-term assay validation, and pharmacokinetic profiling Established programmes, extended longitudinal studies, multi-arm designs Research stage First-time sermorelin research, method development Confirmed design, ongoing programme with validated methods Half-life study design Ideal for repeated pulsatile stimulation assays — shorter windows Extended multi-dose pulsatile protocols across longer timeframes Aliquots available Fewer aliquots — sufficient for focused experimental series Greater aliquot volume — fewer batch changes in extended studies Batch consistency Single-batch for pilot series Extended single-batch — critical for longitudinal reproducibility Cost efficiency Higher per mg — appropriate for pilot stage Better value for active research programmes Comparative studies Single-arm GHRH comparison studies Multi-arm GHRH analogue comparisons alongside CJC-1295, tesamorelin Purity standard ≥98% HPLC-verified (Janoshik) ≥98% HPLC-verified (Janoshik — identical) The sermorelin 2mg laboratory grade format is particularly well-suited to the compound’s primary research application: pharmacokinetic and pulsatile dynamics studies. Because these protocols typically involve multiple small-volume time-point samples rather than large-volume treatment groups, the 2mg format provides sufficient compound volume for a complete pulsatile time-course experimental series without requiring the full
